• Kirenga, Bruce
• Nanzigu, Sarah
• Meya, David
• Musaazi, Joseph
• Kayima, James
• Semakula, Jerome Roy
• Nakibuuka, Jane
• Kwizera, Arthur
• Mwebesa, Henry G.
• Wayengera, Misaki
• Kisuule, Ivan
• Nakwagala, Fred
• Bazeyo, William
• Kamya, Moses R.
• Byakika-Kibwika, Pauline
• Sekaggya-Wiltshire, Christine
• Sendagire, Cornelius

Abstract

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Several repurposed drugs such as hydroxychloroquine (HCQ) have been investigated for treatment of COVID-19, but none was confirmed to be efficacious. While in vitro studies have demonstrated antiviral properties of HCQ, data from clinical trials were conflicting regarding its benefit for COVID-19 treatment. Drugs that limit viral replication may be beneficial in the earlier course of the disease thus slowing progression to severe and critical illness.</jats:p></jats:sec><jats:sec><jats:title>Design</jats:title><jats:p>We conducted a randomized open label Phase II clinical trial from October–December 2020.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Patients diagnosed with COVID-19 using RT-PCR were included in the study if they were 18 years and above and had a diagnosis of COVID-19 made in the last 3 days. Patients were randomized in blocks, to receive either HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days plus standard of care (SOC) treatment or SOC treatment alone. SARS COV-2 viral load (CT values) from RT-PCR testing of samples collected using nasal/orapharyngeal swabs was performed at baseline, day 2, 4, 6, 8 and 10. The primary outcome was median time from randomization to SARS COV-2 viral clearance by day 6.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Of the 105 participants enrolled, 55 were assigned to the intervention group (HCQ plus SOC) and 50 to the control group (SOC only). Baseline characteristics were similar across treatment arms. Viral clearance did not differ by treatment arm, 20 and 19 participants respectively had SARS COV-2 viral load clearance by day 6 with no significant difference, median (IQR) number of days to viral load clearance between the two groups was 4(3–4) vs 4(2–4): p = 0.457. There were no significant differences in secondary outcomes (symptom resolution and adverse events) between the intervention group and the control group. There were no significant differences in specific adverse events such as elevated alkaline phosphatase, prolonged QTc interval on ECG, among patients in the intervention group as compared to the control group.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Our results show that HCQ 400 mg twice a day for the first day followed by 200 mg twice daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda.</jats:p><jats:p><jats:italic>Trial registration: </jats:italic>NCT04860284.</jats:p></jats:sec>

Topics

• phase
• size-exclusion chromatography